FORM 4
[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).         
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
                                                                                  
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response...
0.5                       
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                      

1. Name and Address of Reporting Person *

Kaba Samer
2. Issuer Name and Ticker or Trading Symbol

ALIMERA SCIENCES INC [ ALIM ]
5. Relationship of Reporting Person(s) to Issuer (Check all applicable)

_____ Director                    _____ 10% Owner
__X__ Officer (give title below)    _____ Other (specify below)
Chief Medical Officer
(Last)          (First)          (Middle)

6120 WINDWARD PARKWAY, SUITE 290
3. Date of Earliest Transaction (MM/DD/YYYY)

9/13/2019
(Street)

ALPHARETTA, GA 30005
(City)        (State)        (Zip)
4. If Amendment, Date Original Filed (MM/DD/YYYY)

 
6. Individual or Joint/Group Filing (Check Applicable Line)

_X _ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3)
2. Trans. Date 2A. Deemed Execution Date, if any 3. Trans. Code
(Instr. 8)
4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4)
6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock  9/13/2019    A(1)    1736  A $0.41  72736  D   

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 3)
2. Conversion or Exercise Price of Derivative Security 3. Trans. Date 3A. Deemed Execution Date, if any 4. Trans. Code
(Instr. 8)
5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
6. Date Exercisable and Expiration Date 7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4)
8. Price of Derivative Security
(Instr. 5)
9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares

Explanation of Responses:
(1)  These shares were acquired pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 4, 2019.

Reporting Owners
Reporting Owner Name / Address
Relationships
Director 10% Owner Officer Other
Kaba Samer
6120 WINDWARD PARKWAY
SUITE 290
ALPHARETTA, GA 30005


Chief Medical Officer

Signatures
/s/ Samer Kaba 9/17/2019
**Signature of Reporting Person Date


Alimera Sciences (NASDAQ:ALIM)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more Alimera Sciences Charts.
Alimera Sciences (NASDAQ:ALIM)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more Alimera Sciences Charts.

Alimera Sciences Inc News

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.
Alimera Sciences to Report First Quarter 2024 Financial Results on May 14, 2024, and Provide Corporate Update
Tuesday 30 April 2024 (15 hours ago) • GlobeNewswire Inc.
Alimera Sciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Wednesday 20 March 2024 (1 month ago) • GlobeNewswire Inc.
Alimera Announces First Patient Randomized in Radiation Retinopathy Trial Being Conducted by the DRCR Retina Network
Tuesday 19 March 2024 (1 month ago) • GlobeNewswire Inc.
Form S-8 - Securities to be offered to employees in employee benefit plans
Friday 8 March 2024 (2 months ago) • Edgar (US Regulatory)
Form 8-K - Current report
Thursday 7 March 2024 (2 months ago) • Edgar (US Regulatory)
Alimera Sciences Reports Fourth Quarter and Full Year 2023 Results
Thursday 7 March 2024 (2 months ago) • GlobeNewswire Inc.
Alimera Sciences to Report Fourth Quarter and Full Year 2023 Financial Results on March 7, 2024, and Provide Corporate Update
Thursday 29 February 2024 (2 months ago) • GlobeNewswire Inc.
Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
Tuesday 13 February 2024 (3 months ago) • Edgar (US Regulatory)
Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
Tuesday 13 February 2024 (3 months ago) • Edgar (US Regulatory)
Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
Tuesday 13 February 2024 (3 months ago) • Edgar (US Regulatory)
Form S-8 - Securities to be offered to employees in employee benefit plans
Friday 9 February 2024 (3 months ago) • Edgar (US Regulatory)
Form S-8 - Securities to be offered to employees in employee benefit plans
Friday 9 February 2024 (3 months ago) • Edgar (US Regulatory)